title: Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
abstract: Glycemic regulation improves myocardial function in diabetic patients, but finding optimal therapeutic strategies remains challenging. Recent data have shown that pharmacological inhibition of soluble epoxide hydrolase (sEH), an enzyme that decreases the endogenous levels of protective epoxyeicosatrienoic acids (EETs), improves glucose homeostasis in insulin-resistant mice. Here, we tested whether the administration of sEH inhibitors preserves cardiac myocyte structure and function in hyperglycemic rats. University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk. Administration of APAU attenuated the progressive increase of blood glucose concentration and preserved mitochondrial structure and myofibril morphology in cardiac myocytes, as revealed by electron microscopy imaging. Fluorescence microscopy with Ca(2+) indicators also showed a 40% improvement of cardiac Ca(2+) transients in treated rats. Sarcoplasmic reticulum Ca(2+) content was decreased in both treated and untreated rats compared with control rats. However, treatment limited this reduction by 30%, suggesting that APAU may protect the intracellular Ca(2+) effector system. Using Western blot analysis on cardiac myocyte lysates, we found less downregulation of sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA), the main route of Ca(2+) reuptake in the sarcoplasmic reticulum, and lower expression of hypertrophic markers in treated versus untreated UCD-T2DM rats. In conclusion, APAU enhances the therapeutic effects of EETs, resulting in slower progression of hyperglycemia, efficient protection of myocyte structure, and reduced Ca(2+) dysregulation and SERCA remodeling in hyperglycemic rats. The results suggest that sEH/EETs may be an effective therapeutic target for cardioprotection in insulin resistance and diabetes.
authors.affiliation: Department of Pharmacology, University of California, Davis, CA 95616, USA.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Guglielmino
authors.forename: Kaleena
authors.initials: K
authors.lastname: Jackson
authors.forename: Todd R
authors.initials: TR
authors.lastname: Harris
authors.forename: Vincent
authors.initials: V
authors.lastname: Vu
authors.forename: Hua
authors.initials: H
authors.lastname: Dong
authors.forename: Gavin
authors.initials: G
authors.lastname: Dutrow
authors.forename: James E
authors.initials: JE
authors.lastname: Evans
authors.forename: James
authors.initials: J
authors.lastname: Graham
authors.forename: Bethany P
authors.initials: BP
authors.lastname: Cummings
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Havel
authors.forename: Nipavan
authors.initials: N
authors.lastname: Chiamvimonvat
authors.forename: Sanda
authors.initials: S
authors.lastname: Despa
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Hammock
authors.forename: Florin
authors.initials: F
authors.lastname: Despa
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015153:Blotting, Western; D020013:Calcium Signaling / Q000187:drug effects; D003433:Crosses, Genetic; D048909:Diabetes Complications / Q000097:blood / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D004195:Disease Models, Animal; D018450:Disease Progression; D015777:Eicosanoids / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006331:Heart Diseases / Q000097:blood / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D046529:Microscopy, Electron, Transmission; D008856:Microscopy, Fluorescence; D008929:Mitochondria, Heart / Q000187:drug effects / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D009210:Myofibrils / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011924:Rats, Zucker; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C557705:1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea; D001786:Blood Glucose; D015777:Eicosanoids; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D014508:Urea; D004851:Epoxide Hydrolases; C529022:EPHX2 protein, rat; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D000218:Adamantane